Abstract
Less than a month into 2025 Insilico Medicine has been peppering the AI drug discovery space with much needed good news. The Boston-based group has in the last three weeks announced positive data from two phase I studies, a licensing agreement, the start of a phase I study and a $100m fundraise.
Key Data
-
Publication Date24 January 2025
-
Primary AuthorLisa Urquhart
-
SourceFuture Medicine AI
-
LanguageEnglish
Click below to visit original source: